A Phase Ib Study of the Combination of Personalized Autologous Dendritic Cell Vaccine, Aspirin, and Standard of Care Adjuvant Chemotherapy Followed by Nivolumab for Resected Pancreatic Adenocarcinoma—A Proof of Antigen Discovery Feasibility in Three Patients
Frontiers in Immunology - Switzerland
doi 10.3389/fimmu.2019.01832
Full Text
Open PDFAbstract
Available in full text
Date
August 8, 2019
Authors
Publisher
Frontiers Media SA